202 related articles for article (PubMed ID: 29655990)
1. Inorganic kernel - Supported asymmetric hybrid vesicles for targeting delivery of STAT3-decoy oligonucleotides to overcome anti-HER2 therapeutic resistance of BT474R.
Shi K; Fang Y; Gao S; Yang D; Bi H; Xue J; Lu A; Li Y; Ke L; Lin X; Jin X; Li M
J Control Release; 2018 Jun; 279():53-68. PubMed ID: 29655990
[TBL] [Abstract][Full Text] [Related]
2. Inorganic Kernel-Reconstituted Lipoprotein Biomimetic Nanovehicles Enable Efficient Targeting "Trojan Horse" Delivery of STAT3-Decoy Oligonucleotide for Overcoming TRAIL Resistance.
Shi K; Xue J; Fang Y; Bi H; Gao S; Yang D; Lu A; Li Y; Chen Y; Ke L
Theranostics; 2017; 7(18):4480-4497. PubMed ID: 29158840
[TBL] [Abstract][Full Text] [Related]
3. Synergistic antitumor efficacy against the EGFRvIII+HER2+ breast cancers by combining trastuzumab with anti-EGFRvIII antibody CH12.
Xu W; Bi Y; Zhang J; Kong J; Jiang H; Tian M; Li K; Wang B; Chen C; Song F; Pan X; Shi B; Kong X; Gu J; Cai X; Li Z
Oncotarget; 2015 Nov; 6(36):38840-53. PubMed ID: 26474285
[TBL] [Abstract][Full Text] [Related]
4. STAT3 activation confers trastuzumab-emtansine (T-DM1) resistance in HER2-positive breast cancer.
Wang L; Wang Q; Gao M; Fu L; Li Y; Quan H; Lou L
Cancer Sci; 2018 Oct; 109(10):3305-3315. PubMed ID: 30076657
[TBL] [Abstract][Full Text] [Related]
5. TNFα-Induced Mucin 4 Expression Elicits Trastuzumab Resistance in HER2-Positive Breast Cancer.
Mercogliano MF; De Martino M; Venturutti L; Rivas MA; Proietti CJ; Inurrigarro G; Frahm I; Allemand DH; Deza EG; Ares S; Gercovich FG; Guzmán P; Roa JC; Elizalde PV; Schillaci R
Clin Cancer Res; 2017 Feb; 23(3):636-648. PubMed ID: 27698002
[TBL] [Abstract][Full Text] [Related]
6. HER2-Targeted PET Imaging and Therapy of Hyaluronan-Masked HER2-Overexpressing Breast Cancer.
Pereira PMR; Ragupathi A; Shmuel S; Mandleywala K; Viola NT; Lewis JS
Mol Pharm; 2020 Jan; 17(1):327-337. PubMed ID: 31804840
[TBL] [Abstract][Full Text] [Related]
7. Inhibitory effects of STAT3 decoy oligodeoxynucleotides on human epithelial ovarian cancer cell growth in vivo.
Zhang X; Liu P; Zhang B; Mao H; Shen L; Ma Y
Int J Mol Med; 2013 Sep; 32(3):623-8. PubMed ID: 23828376
[TBL] [Abstract][Full Text] [Related]
8. A novel humanized MUC1 antibody-drug conjugate for the treatment of trastuzumab-resistant breast cancer.
Wu G; Li L; Qiu Y; Sun W; Ren T; Lv Y; Liu M; Wang X; Tao H; Zhao L; Cao J; He L; Li H; Gu H
Acta Biochim Biophys Sin (Shanghai); 2021 Dec; 53(12):1625-1639. PubMed ID: 34586349
[TBL] [Abstract][Full Text] [Related]
9. miR‑135b‑5p enhances the sensitivity of HER‑2 positive breast cancer to trastuzumab via binding to cyclin D2.
Li Z; Qin Y; Chen P; Luo Q; Shi H; Jiang X
Int J Mol Med; 2020 Oct; 46(4):1514-1524. PubMed ID: 32700749
[TBL] [Abstract][Full Text] [Related]
10. Flubendazole overcomes trastuzumab resistance by targeting cancer stem-like properties and HER2 signaling in HER2-positive breast cancer.
Kim YJ; Sung D; Oh E; Cho Y; Cho TM; Farrand L; Seo JH; Kim JY
Cancer Lett; 2018 Jan; 412():118-130. PubMed ID: 29080749
[TBL] [Abstract][Full Text] [Related]
11. NCAPG confers trastuzumab resistance via activating SRC/STAT3 signaling pathway in HER2-positive breast cancer.
Jiang L; Ren L; Chen H; Pan J; Zhang Z; Kuang X; Chen X; Bao W; Lin C; Zhou Z; Huang D; Yang J; Huang H; Wang L; Hou N; Song L
Cell Death Dis; 2020 Jul; 11(7):547. PubMed ID: 32683421
[TBL] [Abstract][Full Text] [Related]
12. GDNF induces RET-SRC-HER2-dependent growth in trastuzumab-sensitive but SRC-independent growth in resistant breast tumor cells.
Gardaneh M; Shojaei S; Kaviani A; Behnam B
Breast Cancer Res Treat; 2017 Apr; 162(2):231-241. PubMed ID: 28116540
[TBL] [Abstract][Full Text] [Related]
13. Multivalent exposure of trastuzumab on iron oxide nanoparticles improves antitumor potential and reduces resistance in HER2-positive breast cancer cells.
Truffi M; Colombo M; Sorrentino L; Pandolfi L; Mazzucchelli S; Pappalardo F; Pacini C; Allevi R; Bonizzi A; Corsi F; Prosperi D
Sci Rep; 2018 Apr; 8(1):6563. PubMed ID: 29700387
[TBL] [Abstract][Full Text] [Related]
14. Pulsed-laser irradiation of multifunctional gold nanoshells to overcome trastuzumab resistance in HER2-overexpressing breast cancer.
Nunes T; Pons T; Hou X; Van Do K; Caron B; Rigal M; Di Benedetto M; Palpant B; Leboeuf C; Janin A; Bousquet G
J Exp Clin Cancer Res; 2019 Jul; 38(1):306. PubMed ID: 31299997
[TBL] [Abstract][Full Text] [Related]
15. Trastuzumab-Resistant HER2
Wielgos ME; Zhang Z; Rajbhandari R; Cooper TS; Zeng L; Forero A; Esteva FJ; Osborne CK; Schiff R; LoBuglio AF; Nozell SE; Yang ES
Mol Cancer Ther; 2018 May; 17(5):921-930. PubMed ID: 29592880
[TBL] [Abstract][Full Text] [Related]
16. Mycophenolic acid potentiates HER2-overexpressing SKBR3 breast cancer cell line to induce apoptosis: involvement of AKT/FOXO1 and JAK2/STAT3 pathways.
Aghazadeh S; Yazdanparast R
Apoptosis; 2016 Nov; 21(11):1302-1314. PubMed ID: 27651367
[TBL] [Abstract][Full Text] [Related]
17. STAT3 activation in HER2-overexpressing breast cancer promotes epithelial-mesenchymal transition and cancer stem cell traits.
Chung SS; Giehl N; Wu Y; Vadgama JV
Int J Oncol; 2014 Feb; 44(2):403-11. PubMed ID: 24297508
[TBL] [Abstract][Full Text] [Related]
18. CD147 knockdown improves the antitumor efficacy of trastuzumab in HER2-positive breast cancer cells.
Xiong L; Ding L; Ning H; Wu C; Fu K; Wang Y; Zhang Y; Liu Y; Zhou L
Oncotarget; 2016 Sep; 7(36):57737-57751. PubMed ID: 27363028
[TBL] [Abstract][Full Text] [Related]
19. MicroRNA-21 links epithelial-to-mesenchymal transition and inflammatory signals to confer resistance to neoadjuvant trastuzumab and chemotherapy in HER2-positive breast cancer patients.
De Mattos-Arruda L; Bottai G; Nuciforo PG; Di Tommaso L; Giovannetti E; Peg V; Losurdo A; Pérez-Garcia J; Masci G; Corsi F; Cortés J; Seoane J; Calin GA; Santarpia L
Oncotarget; 2015 Nov; 6(35):37269-80. PubMed ID: 26452030
[TBL] [Abstract][Full Text] [Related]
20. Tunicamycin enhances the antitumor activity of trastuzumab on breast cancer in vitro and in vivo.
Han X; Zhang X; Li H; Huang S; Zhang S; Wang F; Shi Y
Oncotarget; 2015 Nov; 6(36):38912-25. PubMed ID: 26498681
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]